SANDU PHARMACEUTICALS LTD.

NSE : NABSE : 524703ISIN CODE : INE751D01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE57.39-0.26 (-0.45 %)
PREV CLOSE ( ) 57.65
OPEN PRICE ( ) 58.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3565
TODAY'S LOW / HIGH ( )56.26 59.40
52 WK LOW / HIGH ( ) 4985
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2023
Profit Before Tax22.17
Adjustment4.78
Changes In working Capital-17.74
Cash Flow after changes in Working Capital9.21
Cash Flow from Operating Activities2.21
Cash Flow from Investing Activities5.37
Cash Flow from Financing Activities5.79
Net Cash Inflow / Outflow13.37
Opening Cash & Cash Equivalents9.39
Cash & Cash Equivalent on Amalgamation / Take over / MergerNA
Cash & Cash Equivalent of Subsidiaries under liquidationsNA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNA
Effect of Foreign Exchange FluctuationsNA
Closing Cash & Cash Equivalent22.76

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.